RA Capital Management, a prominent life sciences investment firm, revealed a new position in Abivax SA (ABVX). According to its quarterly ownership report, the firm acquired 1.13 million American Depositary Shares for a total value of $150.92 million. The holding now represents 1.31% of RA Capital's reported portfolio.
The investment was disclosed in an SEC filing dated August 14, which details positions held as of June 30, 2026. Abivax is a clinical-stage biotechnology company developing treatments for chronic inflammatory diseases. In June 2026, the company announced positive top-line results from its Phase 3 maintenance trial of its lead candidate, obefazimod, for treating ulcerative colitis.